Science & Technology
An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4U44AG074105-02
Award Ceiling
$461K
Award Floor
$461K
Close Date
May 31, 2027
442 days leftTotal Funding
$461K
Expected Awards
1
Posted Date
Sep 15, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-4U44AG074105-02
Description
SBIR Phase Phase II award: "An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients" awarded to Bioprovar Corporation in Houston, Texas. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $461,487. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.